Sublingual Anvirzel in Advance Non-Small Cell Lung Cancer (NSCLC)

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 30, 2014

Primary Completion Date

June 30, 2016

Conditions
Chemotherapeutic Agent ToxicityLung Cancer
Interventions
DRUG

Carboplatin

AUC 6 by vein 7 days after Anvirzel administration in a 21 dayc cycle.

DRUG

Docetaxel

75 mg/m2 by vein 7 days after Anvirzel administration in a 21 day cycle.

DRUG

Anvirzel

"Starting Cohort Dose: 6 mg/m2 given 3 times a day administered sublingually for a 21 day cycle.~Expansion Cohort Starting Dose: Maximum tolerated dose from"

BEHAVIORAL

Questionnaires

Questionnaire completion regarding physical and mental at baseline, 7 days before chemotherapy, day 1 of chemotherapy, day 1 of cycles 2, 3, and 4, and at end of dosing visit.

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Nerium Biotechnology

UNKNOWN

lead

M.D. Anderson Cancer Center

OTHER

NCT01562301 - Sublingual Anvirzel in Advance Non-Small Cell Lung Cancer (NSCLC) | Biotech Hunter | Biotech Hunter